Phio Pharmaceuticals Corp
Research Phio Pharmaceuticals Corp (PHIO) on Bullrun: market cap USD 10.71M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPHIO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 10.71M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 4.14M
- Free cash flow-USD 4.04M
Valuation Snapshot
latest market cap is USD 10.71M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 8.70M | -USD 7.99M | n/a | -1.45 | USD 21.03M | n/a | USD 20.15M |
| FY2024 | USD 0 | -USD 7.15M | -USD 7.11M | n/a | -9.08 | USD 5.38M | USD 0 | USD 4.72M |
| FY2023 | USD 0 | -USD 10.83M | -USD 10.75M | n/a | -46.76 | USD 8.49M | USD 35.00K | USD 7.73M |
| FY2022 | USD 0 | -USD 11.48M | -USD 12.25M | n/a | -10.1 | USD 11.83M | USD 170.00K | USD 10.84M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 10.71M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 12.20M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.12M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.48M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 5.09M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 13.53M | n/a | n/a | n/a |
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Phio Pharmaceuticals Corp's market cap?
Phio Pharmaceuticals Corp's market capitalization is USD 10.71M.
What does Phio Pharmaceuticals Corp do?
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.